383 related articles for article (PubMed ID: 34203923)
1. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C; Cassim S; De Leiris N; Durivault J; Faraggi M; Pagès G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203923
[TBL] [Abstract][Full Text] [Related]
2. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
[TBL] [Abstract][Full Text] [Related]
4. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.
Hu X; Xia F; Lee J; Li F; Lu X; Zhuo X; Nie G; Ling D
Adv Sci (Weinh); 2021 Apr; 8(7):2002545. PubMed ID: 33854877
[TBL] [Abstract][Full Text] [Related]
5. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
6. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
[TBL] [Abstract][Full Text] [Related]
7. Imaging for pancreatic ductal adenocarcinoma.
Horvat N; Ryan DE; LaGratta MD; Shah PM; Do RK
Chin Clin Oncol; 2017 Dec; 6(6):62. PubMed ID: 29307202
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
9. What Can We Learn About Pancreatic Adenocarcinoma from Imaging?
Rosenthal M; Schawkat K; Muftah M; Jajoo K
Hematol Oncol Clin North Am; 2022 Oct; 36(5):911-928. PubMed ID: 36265990
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
11. Patient-Friendly Summary of the ACR Appropriateness Criteria: Staging of Pancreatic Ductal Adenocarcinoma.
Rybicki FJ; Lalani T
J Am Coll Radiol; 2019 Apr; 16(4 Pt A):e15. PubMed ID: 30947954
[No Abstract] [Full Text] [Related]
12. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
13. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
[TBL] [Abstract][Full Text] [Related]
14. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
15. Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.
Torres JB; Knight JC; Mosley MJ; Kersemans V; Koustoulidou S; Allen D; Kinchesh P; Smart S; Cornelissen B
Mol Imaging Biol; 2018 Apr; 20(2):292-299. PubMed ID: 28842811
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.
Kramer-Marek G; Gore J; Korc M
Cancer Lett; 2013 Dec; 341(2):132-8. PubMed ID: 23941833
[TBL] [Abstract][Full Text] [Related]
17. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA; Mees ST
Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
[TBL] [Abstract][Full Text] [Related]
19. Value of unenhanced MRI with diffusion-weighted imaging for detection of primary small (≤20 mm) solid pancreatic tumours and prediction of pancreatic ductal adenocarcinoma.
Park HJ; Jang KM; Song KD; Kim SH; Kim YK; Cha MJ; Choi SY; Min K
Clin Radiol; 2017 Dec; 72(12):1076-1084. PubMed ID: 28784320
[TBL] [Abstract][Full Text] [Related]
20. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy.
Toft J; Hadden WJ; Laurence JM; Lam V; Yuen L; Janssen A; Pleass H
Eur J Radiol; 2017 Jul; 92():17-23. PubMed ID: 28624015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
